ReviewFrontiers in immunology2026
The immunoecology of occult hepatitis B virus infection: genetic remodeling and the immune-mediated microcosm.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult hepatitis B infection (OBI) is characterized by the persistence of replication-competent hepatitis B virus (HBV) DNA in the absence of detectable hepatitis B surface antigen (HBsAg). Although typically clinically silent, OBI remains associated with transfusion-transmitted infection, viral reactivation during immunosuppression, and an increased risk of hepatocellular carcinoma (HCC). The mechanisms underlying this persistent low-replicative state remain incompletely understood. In this review, we summarize current evidence supporting the concept that OBI is maintained through dynamic interactions among viral genetic adaptation, host genetic and epigenetic regulation, and the intrahepatic immune microenvironment. Building upon these observations, we propose the immune-mediated microcosm as a conceptual framework describing how these processes may interact to sustain long-term immune equilibrium. We further discuss emerging evidence for coordinated viral and host genetic remodeling, immunometabolic regulation, and immune checkpoint signaling, while explicitly distinguishing mechanisms supported by direct evidence in OBI from those inferred from chronic hepatitis B, hepatocellular carcinoma, or experimental models. Finally, we examine the implications of this framework for biomarker discovery, risk stratification, and therapeutic development, while emphasizing the current evidential limitations and the need for direct validation in human OBI. Rather than providing a definitive mechanistic model, this framework is intended to facilitate mechanistic investigation, generate experimentally testable hypotheses, and help identify priorities for future research into OBI pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.